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1. Introduction
It has been reported that an enzyme-glycogen phosphorylase [EC 2.4.1.1] histochemical re‐
action is observed in differentiated hepatic or muscular tissues and in some proliferating tis‐
sues including fetus and carcinoma [1,2]. In the human stomach, a phosphorylase reaction
appears in the undifferentiated gastric epithelium at the midpoint of fetal life, and is not de‐
tected in gastric epithelium after birth.
In our previous study we hitochemically demonstrated intense glycogen phosphorylase
(GP) activity in gastric cancer cells, especially well-differentiated adenocarcinoma, and in
the proliferative zone of some intestinal metaplasia (IM), despite phosphorelase being nega‐
tive in normal gastric epithelium, even in its proliferative zone. Detailed histochemical ob‐
servations of the enzyme activity were undertaken on the whole mucous membrane of
surgically resected stomachs. A positive reaction was observed in all of the well-differentiat‐
ed adenocarcinomas, whereas only a few poorly differentiated adenocarcinomas reacted
positively. A positive reaction of the proliferative zone was observed in 69.5% of all meta‐
plastic glands of the stomachs with well-differentiated adenocarcinoma, in 25.7% with poor‐
ly differentiated adenocarcinoma, and only rarely in glands from patients with peptic ulcer.
Moreover, there was an apparent coincidence between the location of well-differentiated ad‐
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enocarcinoma and the distribution of IM with the proliferative zone showing a positive reac‐
tion for GP.
GP plays a central role in the mobilization of carbohydrate reserves in a wide variety of or‐
gans and tissues [3,4]. Mammalian GPs are found in three major isoforms, i. e., muscle, liver
and brain that can be distinguished by functional and structural properties, as well as by the
tissues in which they are predominantly expressed [4-6]. cDNAs encoding the three human
GP isoforms have been cloned and sequenced, and the tissue and organism-specific expres‐
sion patterns and chromosomal localization of GP genes has been clarified [4,7]. Chromo‐
some mapping analyses have revealed that the genes encoding muscle, liver and brain GP
are assigned to chromosomes 11, 14, and 20, respectively, suggesting that distinct cis-acting
elements govern the differential expression of the phosphorylase isoforms in various tissues.
The physiological role of muscle and liver GP is to provide fuel for the energy production
required for muscle contraction and to ensure a constant supply of glucose for extrahepatic
tissues, respectively. However, the physiological role of brain GP is poorly understood, al‐
though brain GP is generally thought to induce an emergency glucose supply during a
stressful and/or ischemic period [4,6,8,9]. In addition, it has been proven that the major iso‐
form of GP found in fetal tissue and tumor tissue is brain GP, and brain GP is identical to
fetal-type GP (FGP) [8,9].
We developed an immunohistochemical method of detecting GP isoforms in human tissues
by using specific antibodies raised against highly purified GP isoforms from rat brain, mus‐
cle and liver, and immunohistochemical staining of GP isoforms was undertaken to define
the type of GP present in well-differentiated adenocarcinoma and in the proliferative zone
of IM of the human stomach. Both the malignant cells of well-differentiated adenocarcinoma
and the proliferative zone of some IM of the stomach were stained when the anti-FGP anti‐
body was used, but not when the other two types were used. The results suggested that the
newly appearing GP in gastric carcinoma was FGP, and it could be one example of fetal pro‐
tein expression in cancer, like α-fetoprotain or carcinoembryonic antigen. Moreover, the pro‐
liferative zone of some IM having FGP (FGP-positive IM) might histogenetically relate to
well-differentiated adenocarcinoma, i. e., FGP-positive IM could be regarded as a precursor
of well-differentiated adenocarcinoma [10].
2. Novel subtyping of IM according to FGP expression
It is generally accepted that IM in the stomach increases the risk of gastric carcinoma [11-15].
A paucity of gene rearrangements is common to IM and carcinoma, which makes it difficult
to establish a direct carcinogenic link between them. IM has been classified into subtypes
with the aim of clarification of gastric carcinogenesis according to different definitions of the
subtypes from the viewpoints of morphologic, enzymatic, and mucin-secreting patterns
[16-19]. In such a classification, the subtyping is complicated and subjective, resulting in the
existence of many variants within it. And also, some studies suggested that IM was a good
marker for high risk of gastric cancer but the subclassification of IM was not important
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[13,20]. A better classification of IM related to carcinogenesis that resolved the discrepancy
between these two opinions would contribute to studying the direct link between gastric
cancer and IM and to follow-up of the high-risk group.
To establish a noble classification of IM from a carcinogenic viewpoint, we studied 136
specimens with gastric carcinoma and the adjacent IM, that were obtained from gastric can‐
cer patients (intestinal type, 72 patients; diffuse type, 64 patients), using specific anti-FGP
antibody, and assessed how FGP expression correlates with subtypes of IM, proliferating
cell nuclear antigen-labeling index, and various oncogene products.
Intestinal-Type Carcinoma (n = 72) IM (n =64)
No. (%) BGP Positive No. (%) BGP Negative No. (%) BGP Positive No. (%) BGP Negative
58 (80)* 14 (19) 56 (88)* 8 (12)
p53 Positivity (%) 42 (72.4) 8 (57.1) 10 (17.9) 0 (0.0)
Diffuse-Type Carcinoma (n = 64) IM (n = 24)
No. (%) BGP Positive No. (%) BGP Negative No. (%) BGP Positive No. (%) BGP Negative
12 (19)* 52 (81) 10 (42)* 14 (58)
p53 Positivity (%) 2 (16.7) 10 (19.2) 0 (0.0) 0 (0.0)
BBGP = brain-type glycogen phosphorylase; IM = intestinal metaplasia.
*P < .001.
Table 1. Incidence of FGP and p53 positivity in gastric carcinoma and IM.
2.1. FGP expression in gastric carcinoma and IM
As shown in Table 1, 80% (58/72) of the intestinal type carcinoma expressed FGP, while 19%
(12/64) of the diffuse type showed positive staining for FGP. The percentage of the immuno‐
histochemical positivity for anti-FGP was significantly greater in intestinal type than in dif‐
fuse type carcinoma (P < 0.001). The IM adjacent to carcinoma was found in 88% (64/72) and
38% (24/64) of intestinal and diffuse type carcinoma cases, respectively. In the intestinal
type, 88% (56/64) of the adjacent IM showed FGP positivity, on the other hand, 42% (10/24)
of the adjacent IM showed anti-FGP antibody reactivity in the diffuse type. The expression
of FGP in the IM adjacent to intestinal carcinoma was significantly higher than in the diffuse
type (P < 0.001).
2.2. Relationship between complete and incomplete IM and expression of FGP in the
generative cells
The expressions of FGP in the generative zone of IM were compared with the type of com‐
plete or incomplete IM. We selected 64 cases in which the adjacent mucosa to intestinal-type
carcinoma was IM. The morphologic and mucin-histochemical examination revealed that 23
(36%) and 41 (64%) cases of the adjacent IM were complete and incomplete, respectively.
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The incidence of incomplete-type IM adjacent to the intestinal type of cancer was significant‐
ly higher than that of complete-type IM. However, there was no significant relationship be‐
tween the conventional subtyping of IM and the expressions of FGP. The FGP expressions in
complete and incomplete IM adjacent to the carcinoma were high in both of them (19/23,
82.6%; 37/41, 90.6%; respectively).
2.3. Proliferating state and FGP-positive IM
The proliferative compartment measured by proliferating cell nuclear antigen (PCNA) stain‐
ing in the FGP-negative IM tend to be confined to the lower layer. In the FGP-positive IM,
however, the PCNA labeling was frequently expanded to the upper layer. The labeling in‐
dex analysis revealed that the index of the FGP-positive IM was significantly higher than
that of the FGP-negative IM, although there was not a significant difference between PCNA
labeling index of FGP-positive carcinoma and that of FGP-negative carcinoma (Figure 1).
Figure 1. Distribution of PCNA labeling index in intestinal-type gastric cancer and adjacent IM with or without FGP
expression. NS: not significant
2.4. Relevance of p53 expression with FGP-positive IM
Abnormal p53 accumulation was observed in 10 of 56 (17.9%) of the FGP-positive IM adja‐
cent to intestinal carcinoma (Table 1). The staining of p53 was restricted to the FGP-positive
IM mainly in their generative zone (Figure 2), and none of the staining was detected in the
FGP-negative IM. In cancer foci, the overexpression of p53 was observed in 42 of 58 (72.4%),
8 of 14 (57.1%), 2 of 12 (16.7%), and 10 of 52 (19.2%) in the intestinal-type carcinomas with or
without FGP or the diffuse-type with or without FGP, respectively. The percentage of p53
staining of intestinal-type carcinoma was significantly higher than that of the diffuse-type (P
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< 0.001), and the intestinal-type carcinoma with FGP tend to be stained with p53 more fre‐
quently than that without FGP. The immunohistochemical staining of APC and c-K-ras was
consistently negative in IM.
Figure 2. Overexpression of p53 protein in FGP-positive IM (arrows).A, p53 staining; B, FGP staining; Bar-100μm
In this study, FGP was expressed in 80% of the intestinal-type carcinoma and in 88% in the
generative zone of IM adjacent to the cancer foci, whereas no positive staining was observed
in the normal gastric mucosa, including its generative zone. The proportion of FGP positivi‐
ty in cancer and IM was significantly greater in intestinal-type carcinoma than in the diffuse-
type (P < 0.001). Thus, these results indicate an apparently close association between FGP-
positive IM and intestinal-type gastric carcinoma. Interestingly, morphologic and mucin
characterization revealed that there was no significant correlation between the subtypes of
IM (i.e., complete or incomplete) and the expression of FGP in the generative cells of IM ad‐
jacent to intestinal-type carcinoma.
The characterization of FGP-positive IM was also conducted in this study, using the PCNA
labeling index and the expression of oncogene products. PCNA staining revealed that there
was an expansion of proliferative compartment in FGP-positive IM and it was significantly
higher in a proliferating state than FGP-negative IM. A comparison of the PCNA labeling
index of FGP-positive IM with that of FGP-negative IM indicated that the labeling index
might predict more than 40% of the FGP positivity. Furthermore, some of the FGP-positive
IMs were coexpressed accumulated p53 in the generative cells, although other oncogene
products (APC and c-K-ras) that are common in the adenoma-carcinoma sequence in the co‐
lon [21] were detected in none of the generative cells of IM. PCNA and p53 have been con‐
sidered to be crucial markers for the demonstration of cell proliferation in the cell cycle
phase [22]. The timing of the genetic alteration of p53 has been investigated in the chain of
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chronic gastritis, IM, dysplasia, and early carcinoma and reported to be an early event in
stomach carcinogenesis [23-25]. Abnormal protein accumulation of p53, however, has not
been well demonstrated in IM. In this study, we detected p53 accumulation in the genera‐
tive cell zone of FGP-positive IM despite sporadic expression. These observations suggest
that the generative cells of FGP-positive IM may deviate from the differentiation and be
blocked from apoptotic cell death. Thus, this novel classification of IM based on the linkage
between the generative cell zone of IM and gastric carcinoma using FGP expression may
open new vistas in research of the carcinogenesis of gastric carcinoma.
3. Gastric and intestinal phenotypes of gastric carcinoma with reference
to expression of FGP
Characterization of differentiated gastric carcinoma, i.e., gastric- and intestinal-phenotypic
classification, has been advocated, mainly from the carcinogenic point of view, using analy‐
sis of the expression of gastric and/or intestinal mucin [26-29]. Carcinoma of the stomach has
long been classified into differentiated type and undifferentiated types according to its his‐
tological morphologic characteristics [30]. Because the differentiated type is closely related
to IM, and the tumor cells often have intestinal properties, the differentiated type is called
intestinal type, while the undifferentiated type is called diffuse type [31]. Some differentiat‐
ed-type carcinoma, however, are composed of cells resembling foveolar epithelium or pylor‐
ic gland cells, indicating that these carcinomas may arise from the proper gastric epithelium.
In recent years, immunohistochemical staining with various mucins has been shown to dis‐
criminate mucins with characteristics of gastric and colonic epithelium, leading to a better
understanding of the background of gastric tumorigenesis [32,33]. However, differentiated
gastric carcinoma is classified into five subtypes, i.e., gastric type, gastric type-dominant
mixed type, intestinal type-dominant mixed type, intestinal type, and null type according to
the relative amount of gastric and intestinal mucins, and this classification is complicated
and may be confusing [29].
In this section, we focused on the relationship between the expression of FGP and gastric
and intestinal mucin in gastric carcinoma, and we propose that FGP expression is a simple
marker for discriminating carcinomas with intestinal phenotype from those with gastric
phenotype. Ninety-six tissues of gastric carcinoma surgically resected from the patients (dif‐
ferentiated type: 46, undifferentiated type: 50) were studied regarding correlation of FGP ex‐
pression with intestinal and gastric phenotypes, determined histologically and
immunohistochemically with the various anti-mucin antibodies (HGM, CD10, MUC2).
3.1. Proportions of gastric and intestinal phenotypes in gastric carcinoma
The FGP expression in gastric carcinoma was seen in 82.6% (38/46) of the differentiated type
and 24.0% (12/50) of the undifferentiated type, and which corresponded well with the re‐
sults of our previous study. Both differentiated and undifferentiated gastric carcinomas
were classified into three subtypes, i.e., gastric, mixed and intestinal types, according to the
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relative amount of gastric (HGM-positive) and intestinal (MUC2 and/or CD10-positive) mu‐
cins and the histological morphology. The proportions of gastric, mixed and intestinal types
in differentiated gastric carcinoma were 13.0%, 47.8% and 39.2%, respectively, while hand,
these proportions in undifferentiated gastric carcinoma were 56.0%, 32.0% and 12.0%, re‐
spectively [Table 2].
Histological type Gastric type Mixed type Intestinal type Total
Differentiated (%) 6 (13.0) 22 (47.8) 18 (39.2) 46 (100.0)
Undifferentiated (%) 28 (56.0) 16 (32.0) 6 (12.0) 50 (100.0)
Total (%) 34 (35.4) 38 (39.6) 24 (25.0) 96 (100.0)
Table 2. Incidence of gastric and intestinal phenotypes in gastric carcinoma.
3.2. Relationship between phenotype and FGP expression
Figure 3 shows combination graphs for the mucin phenotypes of gastric carcinoma and FGP
expression in differentiated adenocarcinoma (A) and undifferentiated adenocarcinoma (B).
In both differentiated and undifferentiated types, the phenotype of gastric and intestinal
mucin expression corresponded very well with FGP expression, that is, almost all carcino‐
mas with gastric type (92.3% and 97.1%, respectively) did not express FGP, whereas almost
all with intestinal type (90.9% and 83.3%, respectively) expressed FGP. However, 97.3% of
the mixed type of differentiated adenocarcinoma expressed FGP, while only 33.3% of the
mixed type of undifferentiated carcinoma expressed FGP.
Figure 3. Combination graphs for mucin phenotype and FGP expression in A differentiated and B undifferentiated
gastric carcinoma. Open bars, FGP-negative; closed bars, FGP-positive.
Recent progress in mucin histochemistry and immunohistochemistry has enabled us to dif‐
ferentiate the gastric and intestinal phenotypic properties of gastric carcinoma [C4, 7, 8].
However, in considerable numbers of gastric carcinomas that do not have typical and/or
sufficient mucins (47.8% of the differentiated carcinomas in our study), it is difficult to de‐
cide the phenotype, and this leaves an equivocal group in this classification. Our study re‐
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vealed that almost all the phenotypes decided on by FGP expression corresponded with the
results obtained with mucin immunohistochemistry and H&E staining, suggesting that FGP
expression can discriminate the gastric and intestinal phenotypes in gastric carcinoma. We
assume that this is not because FGP directly contributes to mucin carbohydrate expression,
but probably because FGP-positive gastric carcinoma has intestinal-type lineage, leading to
concordance with intestinal-type mucin expression findings. Accordingly, the mixed type
carcinomas determined by mucin analysis were divided into two groups (gastric and intesti‐
nal types) according to FGP expression. Classification due to FGP expression can be ach‐
ieved more easily, objectively, and simply than classification via the combined analysis of
mucin immunohistochemistry.
Of note, this study also showed that the undifferentiated type of gastric cancer had gastric
and intestinal phenotypes. Furthermore, in undifferentiated adenocarcinoma, the phenotype
determined via mucin analysis corresponded with that determined via FGP expression.
These results suggest that undifferentiated adenocarcinoma with FGP expression may arise
from IM, while those without FGP expression arise from proper gastric epithelium, as has
long been indicated [C5, 6].
Figure 4. Relevance of FGP expression in the carcinogenesis of gastric and intestinal phenotypes of gastric carcinoma.
Diff-type: Differentiated type, Undiff-type: Undifferentiated type, IM: intestinal metaplasia
A schema for our hypothesis derived from this study is shown in Figure 4. The ratios of dif‐
ferentiated and undifferentiated gastric cancers in FGP-positive and FGP-negative carcino‐
mas were around 8:2 and 2:8, respectively. In a previous investigation, we found that FGP-
positive proliferating cells in the IM appeared to be premalignant cells of intestinal-type
carcinoma of the stomach. Therefore, it is suggested that approximately 80% and 20% of the
differentiated and undifferentiated cancers, respectively, arise from FGP-positive proliferat‐
ing cells of IM. On the other hand, approximately 20% and 80% of the differentiated and un‐
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differentiated cancers, respectively, arise from proper gastric mucosa, but candidates for the
premalignant cells in proper gastric mucosa have not yet been suggested.
4. FGP expression in stomachs as a predictive risk factor for the
synchronous and/or metachronous multiple gastric cancer
The recent advantage of endoscopic and laparoscopic local treatments has offered a better
quality  of  life  to  patients  with early gastric  cancer  involving no lymph node metastasis
[34-38].  These  treatments,  however,  incur  increasing  risks  of  missing  the  coexistence  of
accessory or microscopic carcinomas and/or developing new cancers in the remnant stom‐
ach [39-42]. The incidence of multiple primary gastric carcinomas has been reported to be
from 5% to 10% in patients who had gastrectomy for gastric cancer [43-47]. The incidence
is elevated with age and male sex, and with intestinal-type tumors; frequent occurrence in
the lower third, and mucosal cancers, were significantly correlated with multiple early gastric
cancer.  However,  these  accessory  lesions  were  missed  preoperatively  in  approximately
30%-40% of the patients with multifocal  early gastric  cancers.  Furthermore,  considerable
numbers  of  microscopic  cancers  could  have  been  overlooked.  Therefore,  we  should  al‐
ways remember that other lesions may also be present and/or grow when we are treating
patients with gastric cancer by local treatment such as endoscopic treatment or laparoscop‐
ic wedge resection.
Local treatment for early gastric cancer is currently indicated mainly for intestinal-type car‐
cinoma. If there were some indicators that predict the frequent coexistence of multiple gas‐
tric cancers and/or the metachronous growth of another gastric cancer of the intestinal-type,
these would be very useful to identify the high-risk group and would contribute to the fol‐
low-up examinations after local treatment of gastric cancer patients. Our previous studies
have demonstrated the significant role of the generative cells of FGP-positive IM as a prema‐
lignant lesion of intestinal-type gastric carcinoma.
Then, we designed the study to investigate the incidence of FGP-positive IM in gastric biop‐
sy specimens and to establish FGP-positive IM as a predictor of the coexistence of accessory
carcinoma and/or metachronous cancers before and after local treatment for early gastric
cancer. Fifty-nine patients with intestinal-type early gastric cancer and endoscopic atrophic
gastritis were analyzed. Of these patients, 14 had synchronous multiple gastric carcinomas,
25 had a single cancer, 20 had endoscopic atrophic gastritis without any localized lesions.
During endoscopic examination, the lower two-thirds of the stomach was dyed with meth‐
ylene blue and eight endoscopic biopsies were made from the stained mucosa in the anteri‐
or, posterior, greater and lesser curvature wall of the antrum and lower body of the
stomach, respectively. Clinicopathological features of the patients showed that the patients
with multiple early gastric carcinomas were significantly older than those with single early
gastric carcinoma. However, there was no significant difference with the other parameters
among the three groups.
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Figure 5. Immunohistochemical staining of biopsy specimens with anti-FGP antibody.a FGP-positive carcinoma, ×60; b
high-power view, ×260; c FGP-positive IM, ×60; d high-power view, ×260
4.1. FGP expression in endoscopic biopsy specimens of gastric carcinoma and IM
Strongly positive reactivity was observed in the cytoplasm of cancer cells. In 93.3% (28/30) of
the multiple carcinomas and 80.0% (20/25) of the single carcinomas, the biopsy specimens
showed positive staining for FGP. The percentage of immunohistochemical positivity for an‐
ti-FGP antibody in the intestinal-type carcinoma corresponded well with previous our re‐
ports. The IM glands had structural deformity to a slight degree, but no cellular atypia. The
generative cell zone of IM showed positive reactivity. Strong reactivity, similar to that in the
cancer cells, was observed in the cytoplasm of the generative cells of IM (Figure 5).
4.2. Incidence of FGP-positive IM in stomachs with multiple carcinoma, single carcinoma
and atrophic gastritis
Incidence of FGP-positive IM is shown in Figure 6. The distribution of the plots showing
FGP-positive IM in the stomach was extremely characteristic in each group. The distribution
was almost symmetrical in the multiple carcinoma and the atrophic gastritis groups. Al‐
though almost all stomachs with atrophic gastritis had no FGP-positive IM in any biopsy
specimens, all the stomachs with multiple carcinomas had FGP-positive IM in each of the
biopsy specimens. Furthermore, all the carcinomas in the multiple carcinoma group had
high percentages of FGP-positive IM appearance, except for two in which FGP was negative
in the cancer foci. On the other hand, a bipolarized distribution of the plots was observed in
the single-carcinoma group; that is, about a quarter of the group had FGP-positive IM at
high percentages, but about half of the group did not have it at all. The incidences of FGP-
positive IM in the stomachs with multiple carcinomas, single carcinoma and atrophic gastri‐
tis were 83.2% ± 22.8%, 36.5% ± 41.3% and 7.1% ± 18.0%, respectively. The incidence of FGP-
positive IM in the stomachs with multiple carcinomas was significantly higher than that in
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those with a single carcinoma or those with atrophic gastritis. The incidence in stomachs
with a single carcinoma was significantly higher than that in those with atrophic gastritis.
Figure 6. Distribution of incidence of FGP-positive IM in multiple carcinomas, single-carcinoma and atrophic gastri‐
tis groups.
4.3. Useful predictor for the development of new lesions after local treatment for early
gastric cancer
One of the major problems with the local treatment of gastric cancer is that of the metachro‐
nous carcinomas in other parts of the stomach being different from the initial site of the car‐
cinoma. A recent molecular biological study has suggested that high microsatellite
instability in gastric tumors had a relationship with synchronous and/or metachronous gas‐
tric cancer compared with single carcinoma, whereas there was no difference in proliferative
ability, carcinogenic pathway through p53 or K-ras, and various mismatch repair genes, al‐
though the mechanism was unclear [48]. However, the application of molecular genetics in
the screening and surveillance of the patients with gastric cancer is still in its infancy. Arima
et al. reported that metachronous recurrence was found in 6 of 76 endoscopically treated pa‐
tients, and it was detected significantly more frequently in patients whose synchronous mul‐
tiple lesions were found during the initial treatment; they stressed the importance of the
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detection of gastric mucosal recurrence by frequent periodic endoscopic examinations dur‐
ing the follow-up period after the endoscopic treatment [41]. Early detection of the meta‐
chronous cancer is beneficial for the subsequent treatment of the new lesion, for which
minimally invasive therapy, including endoscopic treatment, can be used. The necessity for
frequent endoscopic follow-up, however, affects the quality of life for the patients and in‐
creases the overall medical cost. Therefore, a reliable predictive indicator of patients with a
high risk of metachronous recurrence is very important for determining the schedule of en‐
doscopic follow-up after the initial endoscopic treatment. Because metachronous recurrence
was detected significantly more frequently in patients with synchronous multiple lesions
[35,36,41], a predictive indicator for metachronous recurrence would correspond with the in‐
dicator for synchronous multiple gastric carcinoma.
Wittekind et al. analyzed 61 patients with synchronous gastric carcinoma from among 1664
patients, and suggested that multiple primary tumors arose from precancerous conditions
leading to similar genetic alterations [47]. It is generally accepted that IM in the stomach
increases the risk of gastric cancer [11-14]. However, it has been suggested that only 0.1-0.2%
of IM is related to the carcinogenesis of intestinal-type gastric cancer worldwide [49]. There‐
fore, the IM significantly correlated with carcinogenesis of intestinal-type cancer should be
selected for use as an appropriate marker. Our previous consecutive studies revealed that the
proportion of FGP positivity in both cancer and IM was significantly greater in the intestinal-
type carcinoma than in the diffuse-type; also, we found that FGP-positive IM had a much
stronger correlation with gastric carcinoma than the conventional typing of IM, and FGP-
positive IM was significantly higher in proliferating state than in those samples without FGP,
and p53 mutation occurred only in FGP-positive IM, suggesting that FGP-positive IM is a
precancerous condition for intestinal-type carcinoma [10,50-53]. Thus, our findings indicate
that FGP-positive IM is an excellent marker of the early stage of gastric carcinogenesis.
We also clearly demonstrated that the incidence of FGP-positive IM appearance was signifi‐
cantly more frequent in the stomachs with multiple gastric carcinomas than in those with
single carcinoma or those with atrophic gastritis. The finding that some of the stomachs with
a single carcinoma had a high incidence of FGP-positive IM may suggest the coexistence of
microscopic intestinal-type carcinomas or the possibility of metachronous recurrence in the
future. Assay of FGP in IM by immunohistochemistry in endoscopic biopsy specimens is an
easy and reliable technique to assess FGP-positive IM status in the stomach, and thus could
serve as a predictor of the high potential of a stomach in which synchronous gastric carcino‐
ma coexists for generating metachronous gastric carcinoma. These results suggest that the
analysis of FGP expression in IM in biopsy specimens will contribute to the pre- and postop‐
erative assessment of multiple and metachronous gastric cancer.
Most gastric cancers of the intestinal type are known to occur on the distal side of the endo‐
scopic atrophic border [54,55]. We agree with both the opinion that “the surgeon is required
to resect the area including the F-line at the time of distal gastrectomy so as not to leave an‐
other cancer in the gastric remnant” [54] and the opinion that “the treatment of multiple gas‐
tric cancer does not require extended operative procedure, and endoscopic resection may be
indicated if each lesion fits the criteria for treatment and careful follow-up is ensured” [56].
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The important thing is to have a good predictor for metachronous recurrence after local
treatment [41,48]. Our study demonstrated that FGP-positive IM was detected even in the
stomachs with endoscopic atrophic gastritis without any malignant lesion, suggesting that
FGP-positive IM was not a pathological entity which was associated with the change of a
carcinogenic microenvironment in the gastric mucosa. Therefore, FGP can serve as a poten‐
tial predictor for the risk-assessment of the development of multiple and/or metachronous
carcinomas. It may be possible to follow-up new lesions by this method, and follow-up
studies will give better information on whether FGP-positive IM positivity could be a good
predictor for metachronous recurrence after local treatment.
5. Conclusion
We have proposed that the novel classification of IM based on the linkage between the gen‐
erative cell zone of IM and gastric carcinoma using FGP expression. And also, the classifica‐
tion of gastric and intestinal phenotypes of gastric carcinoma is simpler and clearer when
FGP expression is used than when mucin immunohistochemical analysis is used. It is sug‐
gested that FGP is a useful biomarker for the classification of intestinal and gastric types of
carcinoma of the stomach, including classification from the carcinogenic point of view. And
lastly we demonstrated the importance of FGP-positive IM as a predictor for the metachro‐
nous recurrence of gastric carcinoma, and we propose immunohistochemical staining of
FGP in multiple endoscopic biopsy specimens as a predictive indicator of synchronous can‐
cer and/or metachronous recurrence.
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